Patient Experience of Sentinel Lymph Node Biopsy for Melanoma

Sentinel lymph node biopsy (SLNB) has become an established investigation for assessing microscopic nodal metastasis in melanoma. In a 10-year review of SLNB for melanoma at a single institution, our unit reported a complication rate of 6%1. Despite the widespread use of SLNB for melanoma there are no studies that evaluate patient experience. A method of identifying this information is the study of patient reported outcome measures (PROMs), defined by the Food and Drug Administration as a "measurement of any aspect of a patient's health status that comes directly from the patient".

http://ift.tt/2mAZOqM